Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Inclusion Criteria:

- The patient has a diagnosis of asthma as defined by the NIH

- The patient has persistent asthma with a FEV1 ≥50% and ≤90% of the value predicted for
age, height, sex, and race at the screening visit (SV).

- The patient's persistent asthma is stable and is currently being treated with stable
asthma therapy for at least 30 days before the SV.

- The patient (with assistance from parents/legal guardians/caregivers, as needed) is
able to perform technically acceptable lung function assessments by handheld device

- The patient (with assistance from parents/legal guardians/caregivers, as needed) is
able to use an MDI device and an MDPI device.

- All patients must be able to replace their current SABA with albuterol/salbutamol HFA
MDI inhalation aerosol at the SV for use as needed for the duration of the study

- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

- The patient has a history of life-threatening asthma exacerbation that is defined for
this protocol as an asthma episode that required intubation and/or was associated with
hypercapnia, respiratory arrest, or hypoxic seizures.

- The patient is pregnant or lactating or plans to become pregnant during the study
period or within 30 days after the patient's last study-related visit.

- The patient has a known hypersensitivity to any corticosteroid, salmeterol, or any of
the excipients in the IMP or rescue medication formulation (ie, lactose).

- The patient has been treated with any known strong cytochrome P450 (CYP) 3A4
inhibitors (eg, ketoconazole, ritonavir, clarithromycin) within 30 days before the SV
or plans to be treated with any strong CYP3A4 inhibitor during the study.

- The patient currently smokes or has a smoking history. The patient must not have used
tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or
pipe tobacco).

- The patient has had an asthma exacerbation requiring systemic corticosteroids within
30 days before the SV or has had any hospitalization for asthma within 2 months before
the SV.

- The patient has used immunosuppressive medications within 30 days before the screening
visit.

- The patient has untreated oral candidiasis at the SV. Patients with clinical visual
evidence of oral candidiasis who agree to receive treatment and comply with
appropriate medical monitoring may enter the run-in period.

- The patient has a history of a positive test for human immunodeficiency virus, active
hepatitis B virus, or hepatitis C infection.

- The patient is an immediate relative of an employee of the clinical investigational
center.

- A member of the patient's household is participating in the study at the same time

- Vulnerable patients (ie, people kept in detention) are excluded from participation.

- Additional criteria apply, please contact the investigator for more information